Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2439291 | 0.86 | EGLN1 (0.52) | EGLN1HIF1A | |
| SCHEMBL2439546 | 0.82 | EGLN1 (0.51) | EGLN1HIF1A | |
| SCHEMBL2437583 | 0.82 | EGLN1 (0.48) | EGLN1HIF1A | |
| SCHEMBL2439058 | 0.81 | EGLN1 (0.57) | EGLN1HIF1A | |
| SCHEMBL2435418 | 0.76 | EGLN1 (0.43) | EGLN1HIF1A | |
| SCHEMBL2434412 | 0.76 | EGLN1 (0.43) | EGLN1HIF1A | |
| SCHEMBL2439598 | 0.74 | EGLN1 (0.55) | EGLN1HIF1A | |
| SCHEMBL2436383 | 0.73 | EGLN1 (0.50) | EGLN1HIF1A | |
| SCHEMBL2441228 | 0.71 | EGLN1 (0.58) | EGLN1HIF1A | |
| SCHEMBL2443698 | 0.71 | EGLN1 (0.60) | EGLN1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142509-B1 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC (US) | 2013-12-04 | — | — | EP | claimed |
| US-8048894-B2 | Quinolones and azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2011-11-01 | — | — | US | claimed |
| EP-2142509-A2 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | Amgen, Inc (US) | 2010-01-13 | — | — | EP | claimed |
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | AMGEN INC. (US) | 2009-06-18 | — | — | US | claimed |
| WO-2008130600-A2 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2008-10-30 | — | — | WO | claimed |
| EP-2142509-B1 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8349868-B2 | Azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349868-B2 | Azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8048894-B2 | Quinolones and azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048894-B2 | Quinolones and azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048894-B2 | Quinolones and azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110224248-A1 | AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224248-A1 | AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2142509-A2 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | Amgen, Inc (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008130600-A2 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130600-A2 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | EGLN3, HIF1AN, EGLN2 | EGLN1 6/4885HIF1A 5/4885 |
| US-20110224248-A1 | AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885HIF1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.